Internal Medicine Alert - January 30, 2011

Target Audience:

This activity is intended for the internist and family practitioner.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 1.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Internal Medicine Alert has been reviewed and is acceptable for up to 1 Prescribed credit by the American Academy of Family Physicians. AAFP accreditation begins 01/01/11. Term of approval is for one year from this date. Credit may be claimed for 1 year from the date of each issue.

Faculty

Executive Editor
Stephen A. Brunton, MD

Clinical Professor
University of California, Irvine

Associate Editors
Rahul Gupta, MD, MPH, FACP
Clinical Assistant Professor
West Virginia University School of Medicine
Charleston, WV

Andrew J. Boyle, MBBS, PhD
Assistant Professor of Medicine
Interventional Cardiology
University of California
San Francisco

Mary Elina Ferris, MD
Clinical Associate Professor
University of Southern California

Barbara A. Phillips, MD, MSPH
Professor of Medicine,
University of Kentucky;
Director, Sleep Disorders Center,
Samaritan Hospital,
Lexington

William T. Elliott, MD, FACP
Chair, Formulary Committee
Northern California Kaiser Permanente
Asst. Clinical Professor of Medicine
University of California
San Francisco

James Chan, PharmD, PhD
Pharmacy Quality and Outcomes Manager
Kaiser Permanente
Oakland, CA

Louis Kuritzky, MD
Clinical Assistant Professor
University of Florida
Gainesville

Peer Reviewer
Gerald Roberts, MD
Assistant Clinical Professor of Medicine
Albert Einstein College of Medicine
New York, NY

Subjects:

  • For Thyroid, Right Medication at the Right Time Makes a Difference
  • Does Atorvastatin Have Anti-ischemic Effects?
  • Alcohol Use in Older Women
  • Taking Steps to Be Healthier
  • Eribulin Mesylate Injection (Halaven™)
  • Clinical Briefs

Objectives:

  • describe new findings in differential diagnosis and treatment of various diseases
  • describe controversies, advantages, and disadvantages of those advances
  • describe cost-effective treatment regimens
  • describe the pros and cons of new screening procedures.

Financial Disclosure:

Internal Medicine Alert's editor, Stephen Brunton, MD, is a consultant for Amylin, Novo Nordisk, Shionogi Pharma, Takeda, and Teva; he serves on the speakers bureau of Boehringer Ingelheim, Novo Nordisk, and Teva. Associate editors Rahul Gupta, MD, MPH, FACP, Andrew J. Boyle, MBBS, PhD, Mary Elina Ferris, MD, William T. Elliott, MD, FACP, and James Chan, PharmD, PhD, and peer reviewer Gerald Roberts, MD, report no financial relationship to this field of study. Associate editor Barbara A. Phillips, MD, MSPH is a consultant for Cephalon, and serves on the speakers bureaus for Resmed and Respironics. Associate editor Louis Kuritzky, MD is a consultant for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi, Sankyo, Forest Pharmaceuticals, Lilly, Novo Nordisk, Takeda.

Copyright 2011 AHC Media. All rights reserved.